The data, presented in a poster titled "AP402, a bispecific antibody targeting p95HER2 and CD137, shows potent antitumor activity," highlight the therapeutic potential of AP402 to address ...

Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune ...

Pilatus Biosciences Publishes Preclinical Data in Cancer Discovery on PLT012 First-in-Class CD36-Targeting Antibody for Liver ...